Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Various isoforms of the glycolytic enzyme pyruvate kinase are expressed in different cell types. One of these isoforms, Tu M2-PK, is over-expressed in tumor cells and released into body fluids. Plasma determination of Tu M2-PK has been shown to discriminate between benign and malignant lesions. Tu M2-PK was quantitated in the plasma of 50 patients with cervical carcinoma, 10 patients with chronic cervicitis and 10 healthy controls. The concentration of Tu M2-PK was determined by commercial kits using a sandwich enzyme linked immunosorbent assay based on two monoclonal antibodies (clone I and II) specific for Tu M2-PK. The sensitivity of the test for discrimination of malignant from non-malignant condition was 82% with a specificity of 60%. Highly significant statistical difference was found in the means of three groups (P = 0.0002). The present results indicate that Tu M2-PK can be used as a tumor marker in follow-up of patients with cervical carcinoma.
Kaura
Babita
B
Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. babitzjindal@yahoo.com
Bagga
Rashmi
R
Patel
Feruza D
FD
D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011770:Pyruvate Kinase / Q000097:blood*; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology
D014408:Biomarkers, Tumor; D011770:Pyruvate Kinase